Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Mirror Mirror on the Wall, Who Is the Fairest of Them All EDITORIAL Tony S. K. Mok, MD linical application of epidermal growth factor receptor tyrosine kinase inhibitor C(EGFR TKI) as first-line treatment of advanced stage non–small-cell lung cancer with 1,2 EGFR mutation is based on vigorous science. Multiple randomized studies have inde- pendently confirmed gefitinib and erlotinib to be superior to platinum-based doublet che- 3–6 motherapy. Thus, it is natural to ask if gefitinib is better than erlotinib or vice versa. Lim et al. addressed this question with a relatively large case-control study of 121 matched pairs of gefitinib-treated and erlotinib-treated patients. The pair-matching was appropri- ately based on gender, smoking history, performance status, and type of EGFR mutations. Authors reported similar tumor response rate (76.9% versus 74.4%, p = 0.58) and median progression-free survival (PFS) (11.7 versus 9.6 months; p = 0.056) between the gefitinib- and erlotinib-treated groups. Based on the data, Lim et al. concluded equal effectiveness between the two EGFR TKIs. In short of a randomized comparative study, this report pro- vides a relatively fair picture on the choice between gefitinib and erlotinib. But how “fair” is this fair comparison? Limited by retrospective nature of this study, authors can only take on the required action of patient-pairing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Mok, Tony S. K.
Journal of Thoracic Oncology , Volume 9 (4) – Apr 1, 2014
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/mirror-mirror-on-the-wall-who-is-the-fairest-of-them-all-IsHBgl9NvC

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000123
pmid
24736060
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Tony S. K. Mok, MD linical application of epidermal growth factor receptor tyrosine kinase inhibitor C(EGFR TKI) as first-line treatment of advanced stage non–small-cell lung cancer with 1,2 EGFR mutation is based on vigorous science. Multiple randomized studies have inde- pendently confirmed gefitinib and erlotinib to be superior to platinum-based doublet che- 3–6 motherapy. Thus, it is natural to ask if gefitinib is better than erlotinib or vice versa. Lim et al. addressed this question with a relatively large case-control study of 121 matched pairs of gefitinib-treated and erlotinib-treated patients. The pair-matching was appropri- ately based on gender, smoking history, performance status, and type of EGFR mutations. Authors reported similar tumor response rate (76.9% versus 74.4%, p = 0.58) and median progression-free survival (PFS) (11.7 versus 9.6 months; p = 0.056) between the gefitinib- and erlotinib-treated groups. Based on the data, Lim et al. concluded equal effectiveness between the two EGFR TKIs. In short of a randomized comparative study, this report pro- vides a relatively fair picture on the choice between gefitinib and erlotinib. But how “fair” is this fair comparison? Limited by retrospective nature of this study, authors can only take on the required action of patient-pairing

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Apr 1, 2014

References

  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Lynch
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Mitsudomi
  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
    Zhou